Drugs & Blood Products Used to Manage Bleeding Disorders
Armi Pigott, DVM, DACVECC, BluePearl Pet Hospital, Glendale, Wisconsin
Normal hemostasis is a complex process that leads to blood clot formation at the site of blood vessel injury and is divided into stages of primary hemostasis (platelet plug formation), secondary hemostasis (coagulation), or fibrinolysis (clot degradation).1 Disorders can occur in all stages of hemostasis, may be inherited or acquired, and can affect a single stage or multiple stages.2 Basic understanding of these stages can help guide treatment of specific bleeding disorders.
Primary Hemostasis
Primary hemostasis is the process that forms the platelet plug at the site of vessel wall injury and involves complex interactions between the vessel wall, von Willebrand factor, and platelets.1 A disorder of primary hemostasis is a functional or absolute deficiency of one of these components. The most common causes of life-threatening hemorrhage due to disorders of primary hemostasis in veterinary medicine are thrombocytopenia and von Willebrand disease.3
Secondary Hemostasis
Secondary hemostasis includes fibrin formation through the coagulation cascade, which has classically been divided into intrinsic, extrinsic, and common pathways.1,2 Although the extrinsic tissue-factor–dependent pathway has been considered the primary mechanism for initiation of coagulation, the cell-based coagulation model may be a more accurate representation of secondary hemostasis in the body.1,2,4 The classical divisions however can help with understanding diagnostic tests used to identify coagulation defects and choosing appropriate treatments for coagulation disorders.
Inherited clotting factor deficiencies and vitamin K antagonism are the most common causes of failures of secondary hemostasis. Hemophilia A and hemophilia B (inherited factor VIII and factor IX deficiency, respectively) are the most common inherited clotting factor deficiencies.5 Anticoagulant rodenticide ingestion is the most common cause of vitamin K antagonism.6
Fibrinolysis
Fibrinolysis is the normal process of fibrin clot degradation that prevents clots from becoming more extensive than necessary and breaks down clots when no longer needed.1,7
Disorders that increase the rate of fibrinolysis (ie, hyperfibrinolysis, which is a pathophysiologic state) can result in significant bleeding.1,4,7 Hyperfibrinolysis is associated with several acquired and congenital disorders (eg, cavitary effusion, trauma, liver disease, lungworm [Angiostrongylus vasorum] infection).7 A bleeding disorder in greyhounds that results in delayed hemorrhage after trauma or routine surgery is likely an inherited defect in fibrinolysis but is yet to be characterized.7
Treatment & Management
Patients with clinically significant bleeding or a known or suspected bleeding disorder (including major trauma) scheduled to undergo invasive diagnostic or therapeutic procedures should be treated with drugs or blood products appropriate for the underlying etiology to stop, slow, or prevent bleeding. Identifying the underlying cause helps with selection of the correct blood products and drugs.
In cases in which it is possible to provide treatment with multiple blood products, consideration should be given to the total amount that should (or may need to) be administered, current available products, and potential adverse effects. It is helpful to understand how different blood products are derived. For example, cryoprecipitate would generally be considered the blood product of choice for pre-emptive treatment of von Willebrand disease before ovariohysterectomy. To make one unit of cryoprecipitate, one unit of fresh whole blood is centrifuged to make one unit of fresh frozen plasma, which is then processed to make one unit of cryoprecipitate. Fresh whole blood, fresh frozen plasma, and cryoprecipitate all contain an equal amount of von Willebrand factor. Each round of processing concentrates the von Willebrand factor into a smaller volume of blood product; therefore, the difference is the total volume of blood product needed to provide that amount of von Willebrand factor, with fresh whole blood being the largest volume and cryoprecipitate being the smallest. In addition, fresh frozen plasma and cryoprecipitate do not contain RBCs, thus there is less antigenic exposure to the recipient, which is important in patients with a bleeding disorder that may need multiple blood transfusions over their lifetime.
Whole blood doses listed in this article are intended to provide clotting factors or platelets to deficient patients and may differ significantly from the amount of blood needed to treat anemia. Clinically anemic patients may need more, less, or additional RBC-containing products. Transfusions of any blood product should be administered, and patients monitored for adverse transfusion reactions, according to established hospital protocols. The Association of Veterinary Hematology and Transfusion Medicine has published consensus statement guidelines for transfusion monitoring, as well as diagnosing and treating transfusion reactions in small animal patients.8-10
Ideally, patients receiving RBC products should undergo blood typing and crossmatching prior to transfusion; however, these can be skipped in a life-threatening, time-sensitive crisis in dogs receiving a first-time transfusion, as naturally occurring alloantibodies (and, therefore, life-threatening transfusion reactions) are rare in dogs receiving transfusion for the first time. Cats should always undergo blood typing and crossmatching prior to transfusion because they have naturally occurring alloantibodies to multiple red cell antigens that can result in severe, life-threatening transfusion reactions to incompatible blood.
More resources and in-depth discussion of blood typing, crossmatching, and transfusion reactions are available. All blood products discussed in this article are species-specific.
Blood Products
Platelet-Containing Products for Transfusion
Transfused platelets have a relatively fast clearance rate, particularly in patients with immune-mediated thrombocytopenia.3,11 Platelet transfusions are typically reserved for actively bleeding patients with thrombocytopenia or are administered prophylactically to patients with severe thrombocytopenia (ie, platelets, <60,000/µL) about to undergo a surgical procedure.3,11 Prophylactic platelet transfusions should be given immediately preoperatively to maximize benefits.
Platelet-Rich Plasma
Platelet-rich plasma is separated from freshly collected blood within 4 to 6 hours of collection, before refrigeration (39°F [4°C]; standard range for all refrigerated blood products, 33.8°F-42.8°F [1°C-6°C]; hereafter noted as 39°F [4°C]), and using a specialized centrifugation technique to produce supernatant plasma rich in platelets. Platelet-rich plasma has a short shelf life and is typically made on demand by onsite blood banks or as a special order from commercial blood banks.11,12
Indications
Life-threatening hemorrhage due to thrombocytopenia
Prophylaxis prior to invasive diagnostics or surgery in patients with severe thrombocytopenia
Dosage (Dogs, Cats)
10 mL/kg IV transfusion over 1 to 2 hours11
May be administered faster in a hemorrhagic crisis
Patients in a severe bleeding crisis may require a significantly higher dose.
Key Points
Product can be stored refrigerated at 39°F (4°C) for 72 hours from the time of blood collection.11
Frozen Platelet Concentrate
Frozen platelet concentrate can be produced either by further centrifuging platelet-rich plasma to remove some of the plasma volume or by plateletpheresis; it is then preserved in dimethyl sulfoxide (ie, DMSO) solution prior to freezing.3,11,13
Indications
Life-threatening hemorrhage due to thrombocytopenia
Prophylaxis prior to invasive diagnostics or surgery in patients with severe thrombocytopenia
Dosage (Dogs, Cats)
10 mL/kg IV transfusion over 1 to 2 hours11
May be administered faster in a hemorrhagic crisis
Patients in a severe bleeding crisis may require a significantly higher dose.
Key Points
Product can be stored frozen at or below −0.4°F (−18°C) for 6 months from date of production and should be used immediately after thawing in a water bath at 98.6°F (37°C).11
Lyophilized Platelets
Lyophilized platelets are produced by plateletpheresis and subsequent lyophilization, allowing storage at room temperature (64.4°F-86°F [18°C-30°C]) and a longer shelf life.
Indications
Life-threatening hemorrhage due to thrombocytopenia
Prophylaxis prior to invasive diagnostics or surgery in patients with severe thrombocytopenia3,7,11,13,14
Dosage (Dogs, Cats)
3 × 109 platelets/kg or 2 mL/kg when reconstituted according to manufacturer instructions over 15 to 20 minutes11,14
Key Points
Product can be stored at room temperature (64.4°F-86°F [18°C-30°C]) for 2 years from date of production and should be used within 1 hour of reconstitution.14
Currently only available for dogs
Whole Blood (Fresh & Cold-Stored <21 Days)
Whole blood is blood collected from a donor and stored in preservative solution without further alteration or separation into component parts.
Indications
Bleeding due to inherited and acquired coagulation disorders3,7,11,13,14
Dosage (Dogs, Cats)
Initially, 1 unit/10 kg (≈15 mL/kg) IV transfusion over 1 to 4 hours for severe thrombocytopenia, clotting factor deficiency, and vitamin K antagonism3,5,6,11,13,15-18
Additional transfusions as indicated by volume of blood loss, perfusion parameters, and hematocrit
May be administered more rapidly in a hemorrhagic crisis18
10 mL/kg of fresh whole blood is expected to raise the platelet count by ≈10,000/µL
≥20-40 mL/kg typically controls hemorrhage in patients with vitamin K antagonism and inherited coagulopathies
Key Points
Product can be stored refrigerated at 39°F (4°C) up to 21 days from collection for platelet transfusion.18
RBCs remain viable longer, depending on the anticoagulant and cell preservatives added to the collection bag.18
It was previously believed that only fresh whole blood (not blood stored in the refrigerator) contained active platelets, but recent evidence shows refrigerated canine whole blood retains most of its clot strength for up to 21 days.15,16
Cryoprecipitate
Cryoprecipitate is rich in factor VIII, factor XIII, fibrinogen, and von Willebrand factor that is available in lyophilized or frozen forms and is produced from fresh frozen plasma in commercial and onsite blood banks.5
Indications
Bleeding due to von Willebrand disease and hemophilia A5
Dosage (Dogs, Cats)
1 unit/10 kg (≈1 mL/kg) IV transfusion over 30 to 60 minutes for prophylaxis5
1 unit/10 kg (≈1 mL/kg) IV transfusion over 30 to 60 minutes, repeated continuously until bleeding stops for bleeding crisis5
Much larger volumes (ie, ≥10-30 mL/kg) are usually required for hemorrhagic crisis.
Key Points
Frozen product can be stored frozen at or below −0.4°F (−18°C) for 1 year from date of production and should be used within 24 hours of thawing in a water bath at 98.6°F (37°C).11
Lyophilized product can be stored refrigerated at 39°F (4°C) for 18 months from date of production (prior to reconstitution) and should be used within 24 hours of reconstitution.19
Canine product is generally available from most commercial blood banks and can be produced by onsite donor programs with the appropriate type of blood banking centrifuge.
Feline product is usually made to order (resulting in longer delay to shipping) and only available from a few commercial blood banks; however, it can also be made by onsite donor programs with the appropriate type of blood banking centrifuge.
Cryo-Poor Plasma
Cryo-poor plasma (ie, cryosupernatant) is the plasma product that remains after cryoprecipitate has been removed from a processed bag of fresh frozen plasma and contains factors II, VII, IX, X, XI, XII, and XIII, as well as fibrinogen, albumin, and globulins. Cryo-poor plasma is produced in commercial and onsite blood banks.6,20
Indications
Bleeding in patients with hemophilia B
Bleeding crisis due to vitamin K antagonism6,20
Dosage (Dogs, Cats)
1 unit/10 kg (≈8-10 mL/kg) IV transfusion over 1 to 4 hours for prophylaxis
1 unit/10 kg (≈8-10 mL/kg) IV transfusion over 30 to 60 minutes, repeated continuously until bleeding stops for hemophilia B bleeding crisis
20-40 mL/kg IV transfusion over 1 to 4 hours for vitamin K antagonism
Larger volumes often required for patients in bleeding crisis6,20
May be given faster during bleeding crisis6,19
Key Points
Product can be stored frozen at or below −0.4°F (−18°C) for 1 year from date of production and should be used within 4 to 6 hours of thawing in a water bath at 98.6°F (37°C) when used to replace depleted clotting factors.
Product thawed and not used can be kept refrigerated at 39°F (4°C) and used within 2 weeks as refrigerated plasma.21
Fresh Frozen Plasma
Fresh frozen plasma is plasma that has been processed and frozen at or below −0.4°F (−18°C) within 6 to 8 hours of blood collection.20
Indications
Bleeding due to von Willebrand disease, hemophilia A, and vitamin K antagonism5,6
Dosage (Dogs, Cats)
1 unit/10 kg (≈10 mL/kg) IV transfusion over 2 hours for prophylaxis
1 unit/10 kg (≈10 mL/kg) IV transfusion over 2 hours, repeated continuously until bleeding stops for bleeding crisis
May be given faster in severe bleeding crisis5,21
Key Points
Product can be stored frozen at or below −0.4°F (−18°C) for 1 year from date of production and should be used within 4 to 6 hours of thawing in a water bath at 98.6°F (37°C) for treatment of von Willebrand disease.
Product thawed and not used can be refrozen within 24 hours for use as frozen plasma or kept refrigerated at 39°F (4°C) and used within 2 weeks as refrigerated plasma.21
Frozen Plasma
Frozen plasma can be derived by processing and freezing plasma between 8 and 24 hours after blood collection, storing fresh frozen plasma at or below −0.4°F (−18°C) for >1 year, or thawing fresh frozen plasma and storing refrigerated at 39°F (4°C) for >24 hours before transfusion (subsequently called thawed plasma).21
Indications
Bleeding due to von Willebrand disease, hemophilia A, and vitamin K antagonism5,11
Dosage (Dogs, Cats)
1 unit/10 kg (≈10 mL/kg) IV transfusion over 2 hours for prophylaxis5,6,21
1 unit/10 kg (≈10 mL/kg) IV transfusion over 2 hours for bleeding crisis, repeated continuously until bleeding stops
Larger volumes usually required5,6,21
May be given faster in severe bleeding crisis5,21
Key Points
Product can be stored frozen at or below −0.4°F (−18°C) for 1 year from date of production and should be used within 4 to 6 hours of thawing in a water bath at 98.6°F (37°C) for treatment of von Willebrand disease.
Some studies indicate levels of factors V and VIII decrease and possibly become subtherapeutic, depending on length of storage.5,6,21
Product thawed and not used can be refrozen within 24 hours for use as frozen plasma or kept refrigerated at 39°F (4°C) and used within 1 week as thawed plasma.21
Drugs & Nutraceuticals
Vitamin K
Vitamin K supplement; antidote for vitamin K antagonism due to anticoagulant rodenticides
Indications
Treatment of vitamin K antagonism in coagulopathic patients and in subclinical or preclinical patients with vitamin K antagonist exposure
Vitamin K supplement for patients with hepatic disease
Dosage (Dogs, Cats)
1-5 mg/kg PO, IM, or SC every 24 hours or divided and given every 12 hours
Key Points
May take 6 to 12 hours for clinically significant amounts of active clotting factors to be produced once treatment is initiated
Absorption from the GI tract is enhanced when administered with a meal.
Patients with active hemorrhage should be treated with blood products (eg, whole blood, fresh frozen plasma) to stop bleeding and treat anemia (see RBC and plasma products sections).
Coagulopathic patients may bleed from injection sites.
Oral administration can be considered if the GI tract is working.
Small-gauge needles for injection should be used if oral administration is not possible.
Duration of treatment depends on the specific toxin and total amount ingested.
Toxicology reference publications, animal poison control centers, veterinary toxicologists, and product manufacturer instructions should be used to determine duration of treatment.
Desmopressin
Desmopressin is a synthetic analogue of vasopressin.
Indications
Bleeding due to von Willebrand disease5,22
Dosage (Dogs)
1-4 µg/kg SC 30 minutes preoperatively for prophylaxis5,22
4 µg/kg SC once for bleeding crisis5
Key Points
Administration causes release, not production, of stored von Willebrand factor from the endothelium and, therefore, is generally only effective once in a 24-hour period.5
Can be repeated every 24 hours for the duration of a bleeding crisis, although the efficacy of subsequent doses is unknown
Available from most commercial human pharmacies in a nonsterile nasal spray formulation that can be administered SC
No information is available regarding this drug for cats with von Willebrand disease.
Epsilon Aminocaproic Acid
Epsilon aminocaproic acid is an antifibrinolytic drug used to treat hyperfibrinolysis and prevent postoperative bleeding in greyhounds. Either aminocaproic acid or tranexamic acid should be used, not both; choice typically depends on clinician preference and drug availability.
Indications7,23-26
Hyperfibrinolysis
Prophylaxis for postoperative bleeding in greyhounds (and possibly other sighthounds)7,23-26
Dosage (Dogs)
50-100 mg/kg IV or PO every 6 to 8 hours23,24
Key Points
The injectable formulation can also be given orally (in place of tablets if desired and based on availability).
Rapid IV administration may cause bradycardia and hypotension.
Rarely causes GI upset
There are no published data on use of antifibrinolytic drugs in cats.
Tranexamic Acid
Tranexamic acid is an antifibrinolytic drug used to treat hyperfibrinolysis and prevent postoperative bleeding in greyhounds. Either aminocaproic acid or tranexamic acid should be used, not both; choice typically depends on clinician preference and drug availability.
Indications7,25-28
Hyperfibrinolysis
Prophylaxis for postoperative bleeding in greyhounds (and possibly other sighthounds)7,23-26
Dosage (Dogs)
10-20 mg/kg IV over 2 to 20 minutes or PO every 6 to 8 hours28
There are no reported doses for treating coagulopathy in cats.
Key Points
Rapid bolus may cause vomiting in dogs.
One study evaluated surgical blood loss associated with carcinoma and sarcoma mass removal in cats.28 Results showed that 15 mg/kg IV administered at induction reduced surgical blood loss; it is not known how this relates to cats with coagulopathy.
Yunnan Baiyao
Yunnan Baiyao is a Chinese herbal supplement purported to have hemostatic properties.29-32 The active ingredients are unknown and not disclosed by the manufacturer.
Although there is anecdotal evidence supporting use of Yunnan Baiyao, results of studies evaluating effects on coagulation parameters in dogs are inconsistent, with some showing no effect and others showing a change from baseline measurements but generally staying within the normal reference interval. This variation may be secondary to inconsistent ingredients in batches due to lack of regulations in the nutraceutical/supplement industry, use of the wrong type of test to investigate for an effect, or lack of sensitivity of available testing modalities.29-32 In addition, the nutraceutical may not actually alter coagulation. Other limitations include significant variability in administration and patient characteristics among various trials. Clinical studies involved patients with bleeding tumors on the spleen or heart and did not require laboratory evidence of coagulopathy as inclusion criteria. Limited evidence suggests minimal harm secondary to administration of a variety of doses,29-32 but doses that produce consistent effects have not been identified. Based on current available evidence, identification of the underlying cause of coagulopathy and targeted therapy with the evidence-based treatments, as discussed previously, seems most beneficial.